The Management of CKD-MBD in Pediatric Dialysis Patients

[1]  D. Haffner,et al.  Bone evaluation in paediatric chronic kidney disease: Clinical practice points from the European Society for Paediatric Nephrology CKD-MBD and Dialysis working groups and CKD-MBD working group of the ERA-EDTA. , 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  J. Bacchetta,et al.  Physiology of FGF23 and overview of genetic diseases associated with renal phosphate wasting. , 2020, Metabolism: clinical and experimental.

[3]  M. Vervloet,et al.  Cinacalcet use in paediatric dialysis: a position statement from the European Society for Paediatric Nephrology and the Chronic Kidney Disease-Mineral and Bone Disorders Working Group of the ERA-EDTA. , 2019, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[4]  W. Gahl,et al.  Management of bone disease in cystinosis: Statement from an international conference , 2019, Journal of inherited metabolic disease.

[5]  A. Edefonti,et al.  Clinical practice recommendations for growth hormone treatment in children with chronic kidney disease , 2019, Nature Reviews Nephrology.

[6]  B. Bammens,et al.  A distinct bone phenotype in ADPKD patients with end-stage renal disease. , 2019, Kidney international.

[7]  H. Zhang,et al.  Correction to: An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to < 6 years with chronic kidney disease receiving dialysis , 2018, Pediatric nephrology (Berlin, West).

[8]  G. Ariceta,et al.  A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet in pediatric patients with chronic kidney disease and secondary hyperparathyroidism receiving dialysis , 2018, Pediatric Nephrology.

[9]  G. Zilleruelo,et al.  Cinacalcet as rescue therapy for refractory hyperparathyroidism in young children with advanced chronic kidney disease , 2018, Pediatric Nephrology.

[10]  J. Bacchetta,et al.  Bone disease in nephropathic cystinosis is related to cystinosin-induced osteoclastic dysfunction , 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[11]  S. Shahinfar,et al.  An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to < 6 years with chronic kidney disease receiving dialysis , 2018, Pediatric Nephrology.

[12]  W. Gahl,et al.  Skeletal Consequences of Nephropathic Cystinosis , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[13]  I. Salusky,et al.  Clinical experience with the use of ferric citrate as a phosphate binder in pediatric dialysis patients , 2018, Pediatric Nephrology.

[14]  J. Bacchetta,et al.  The interplay between bone and vessels in pediatric CKD: lessons from a single-center study , 2018, Pediatric Nephrology.

[15]  K. Kalantar-Zadeh,et al.  Real-World Scenario Improvements in Serum Phosphorus Levels and Pill Burden in Peritoneal Dialysis Patients Treated with Sucroferric Oxyhydroxide , 2018, American Journal of Nephrology.

[16]  J. Bacchetta,et al.  Teenagers and young adults with nephropathic cystinosis display significant bone disease and cortical impairment , 2018, Pediatric Nephrology.

[17]  J. Ross,et al.  Pediatric Exclusivity and Regulatory Authority: Implications of Amgen v HHS. , 2018, JAMA.

[18]  Ayumi Matsumoto,et al.  Anion Gap as a Determinant of Ionized Fraction of Divalent Cations in Hemodialysis Patients. , 2017, Clinical journal of the American Society of Nephrology : CJASN.

[19]  J. Bacchetta,et al.  Skeletal impairment in Pierson syndrome: Is there a role for lamininβ2 in bone physiology? , 2018, Bone.

[20]  G. Choukroun,et al.  Randomized Clinical Trial of Sevelamer Carbonate on Serum Klotho and Fibroblast Growth Factor 23 in CKD. , 2017, Clinical journal of the American Society of Nephrology : CJASN.

[21]  D. Leaf,et al.  C-Terminal Fibroblast Growth Factor 23, Iron Deficiency, and Mortality in Renal Transplant Recipients. , 2017, Journal of the American Society of Nephrology : JASN.

[22]  A. Go,et al.  Fibroblast Growth Factor 23 and Anemia in the Chronic Renal Insufficiency Cohort Study. , 2017, Clinical journal of the American Society of Nephrology : CJASN.

[23]  D. Mekahli,et al.  Evidence for Bone and Mineral Metabolism Alterations in Children With Autosomal Dominant Polycystic Kidney Disease , 2017, The Journal of clinical endocrinology and metabolism.

[24]  Yuan Cai,et al.  Lanthanum damages learning and memory and suppresses astrocyte–neuron lactate shuttle in rat hippocampus , 2017, Experimental Brain Research.

[25]  Kaleab Z. Abebe,et al.  Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease. , 2017, Clinical journal of the American Society of Nephrology : CJASN.

[26]  A. Edefonti,et al.  Clinical practice recommendations for native vitamin D therapy in children with chronic kidney disease Stages 2-5 and on dialysis. , 2017, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[27]  Mary B Leonard,et al.  Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters. , 2017, Kidney international.

[28]  A. Edefonti,et al.  Clinical practice recommendations for treatment with active vitamin D analogues in children with chronic kidney disease Stages 2-5 and on dialysis. , 2017, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[29]  K. Uhlig,et al.  Effects of Ferric Citrate in Patients with Nondialysis-Dependent CKD and Iron Deficiency Anemia. , 2017, Journal of the American Society of Nephrology : JASN.

[30]  C. Langman.  Bone Complications of Cystinosis. , 2017, The Journal of pediatrics.

[31]  P. Scherer,et al.  Adiponectin alters renal calcium and phosphate excretion through regulation of klotho expression. , 2017, Kidney international.

[32]  E. Valore,et al.  Effects of dietary iron intake and chronic kidney disease on fibroblast growth factor 23 metabolism in wild-type and hepcidin knockout mice. , 2016, American journal of physiology. Renal physiology.

[33]  M. Wolf,et al.  Fibroblast Growth Factor 23 and Risk of CKD Progression in Children. , 2016, Clinical journal of the American Society of Nephrology : CJASN.

[34]  M. Wolf,et al.  Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. , 2016, Kidney international.

[35]  P. Claus,et al.  Fibroblast growth factor 23 signaling in hippocampal cells: impact on neuronal morphology and synaptic density , 2016, Journal of neurochemistry.

[36]  J. Bacchetta,et al.  Pediatric combined liver–kidney transplantation: a single-center experience of 18 cases , 2016, Pediatric Nephrology.

[37]  S. Aberegg.  Ionized Calcium in the ICU: Should It Be Measured and Corrected? , 2016, Chest.

[38]  Thomas O Jemielita,et al.  Fracture Burden and Risk Factors in Childhood CKD: Results from the CKiD Cohort Study. , 2016, Journal of the American Society of Nephrology : JASN.

[39]  M. Wolf,et al.  Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production , 2015, Kidney international.

[40]  A. Cheung,et al.  Low Vitamin D and High Fibroblast Growth Factor 23 Serum Levels Associate with Infectious and Cardiac Deaths in the HEMO Study. , 2016, Journal of the American Society of Nephrology : JASN.

[41]  J. Bacchetta,et al.  Bone impairment in oxalosis: An ultrastructural bone analysis. , 2015, Bone.

[42]  J. Craig,et al.  Interventions for metabolic bone disease in children with chronic kidney disease. , 2015, The Cochrane database of systematic reviews.

[43]  I. Narita,et al.  Administration of Ferric Citrate Hydrate Decreases Circulating FGF23 Levels Independently of Serum Phosphate Levels in Hemodialysis Patients with Iron Deficiency , 2015, Nephron.

[44]  K. Mahaffey,et al.  Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. , 2015, Circulation.

[45]  K. Mahaffey,et al.  Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Heart Failure , 2015 .

[46]  F. Locatelli,et al.  Cysteamine treatment restores the in vitro ability to differentiate along the osteoblastic lineage of mesenchymal stromal cells isolated from bone marrow of a cystinotic patient , 2015, Journal of Translational Medicine.

[47]  H. Malluche,et al.  High Parathyroid Hormone Level and Osteoporosis Predict Progression of Coronary Artery Calcification in Patients on Dialysis. , 2015, Journal of the American Society of Nephrology : JASN.

[48]  H. Jüppner,et al.  Osteocytic Protein Expression Response to Doxercalciferol Therapy in Pediatric Dialysis Patients , 2015, PloS one.

[49]  J. Bacchetta,et al.  Bone impairment in primary hyperoxaluria: a review , 2015, Pediatric Nephrology.

[50]  D. Elashoff,et al.  Effects of acute kidney injury and chronic hypoxemia on fibroblast growth factor 23 levels in pediatric cardiac surgery patients , 2015, Pediatric Nephrology.

[51]  R. Shroff,et al.  The demise of calcium-based phosphate binders—is this appropriate for children? , 2014, Pediatric Nephrology.

[52]  F. Kainberger,et al.  Inverse association between bone microarchitecture assessed by HR-pQCT and coronary artery calcification in patients with end-stage renal disease. , 2014, Bone.

[53]  V. Tasic,et al.  Nephropathic cystinosis--a gap between developing and developed nations. , 2014, The New England journal of medicine.

[54]  S. Rivella,et al.  FGF-23 Is a Negative Regulator of Prenatal and Postnatal Erythropoiesis* , 2014, The Journal of Biological Chemistry.

[55]  B. Lanske,et al.  FGF23 regulates renal sodium handling and blood pressure , 2012, EMBO molecular medicine.

[56]  B. Lanske,et al.  Parathyroid-Specific Deletion of Klotho Unravels a Novel Calcineurin-Dependent FGF23 Signaling Pathway That Regulates PTH Secretion , 2013, PLoS genetics.

[57]  A. De Paepe,et al.  Copper deficiency in patients with cystinosis with cysteamine toxicity. , 2013, The Journal of pediatrics.

[58]  M. Wolf,et al.  Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[59]  C. Betzel,et al.  Modeling of Oxidized PTH (oxPTH) and Non-oxidized PTH (n-oxPTH) Receptor Binding and Relationship of Oxidized to Non-Oxidized PTH in Children with Chronic Renal Failure, Adult Patients on Hemodialysis and Kidney Transplant Recipients , 2013, Kidney and Blood Pressure Research.

[60]  J. Shults,et al.  Vitamin D bioavailability and catabolism in pediatric chronic kidney disease , 2013, Pediatric Nephrology.

[61]  I. D. de Boer,et al.  Mineral metabolism and cortical volumetric bone mineral density in childhood chronic kidney disease. , 2013, The Journal of clinical endocrinology and metabolism.

[62]  C. Shanahan,et al.  Mechanistic insights into vascular calcification in CKD. , 2013, Journal of the American Society of Nephrology : JASN.

[63]  J. Bacchetta,et al.  Fibroblast growth factor 23 inhibits extrarenal synthesis of 1,25‐dihydroxyvitamin D in human monocytes , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[64]  R. Shroff.  Phosphate is a vascular toxin , 2013, Pediatric Nephrology.

[65]  J. Bacchetta,et al.  Beyond mineral metabolism, is there an interplay between FGF23 and vitamin D in innate immunity? , 2013, Pediatric Nephrology.

[66]  D. Haffner,et al.  Searching the optimal PTH target range in children undergoing peritoneal dialysis: New insights from international cohort studies , 2013, Pediatric Nephrology.

[67]  W. Gahl,et al.  Cystinosis: the evolution of a treatable disease , 2012, Pediatric Nephrology.

[68]  J. Bacchetta,et al.  The consequences of chronic kidney disease on bone metabolism and growth in children. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[69]  I. Bhan,et al.  Ergocalciferol and cholecalciferol in CKD. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[70]  C. Langman,et al.  An open-label study to evaluate a single-dose of cinacalcet in pediatric dialysis subjects , 2012, Pediatric Nephrology.

[71]  M. Mitsnefes.  Cardiovascular disease in children with chronic kidney disease. , 2012, Journal of the American Society of Nephrology : JASN.

[72]  R. Shroff,et al.  Ergocalciferol supplementation in children with CKD delays the onset of secondary hyperparathyroidism: a randomized trial. , 2012, Clinical journal of the American Society of Nephrology : CJASN.

[73]  R. Elashoff,et al.  Early skeletal and biochemical alterations in pediatric chronic kidney disease. , 2012, Clinical journal of the American Society of Nephrology : CJASN.

[74]  W. Gahl,et al.  Cysteamine toxicity in patients with cystinosis. , 2011, The Journal of pediatrics.

[75]  A. Go,et al.  FGF23 induces left ventricular hypertrophy. , 2011, The Journal of clinical investigation.

[76]  E. Farrow,et al.  Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice , 2011, Proceedings of the National Academy of Sciences.

[77]  A. Ashraf,et al.  Changes in plasma FGF23 in growth hormone deficient children during rhGH therapy , 2011, Journal of pediatric endocrinology & metabolism : JPEM.

[78]  Huiliang Xie,et al.  Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. , 2011, Kidney international.

[79]  R. Elashoff,et al.  Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. , 2011, Kidney international.

[80]  G. Ariceta,et al.  The bone and mineral disorder of children undergoing chronic peritoneal dialysis. , 2010, Kidney international.

[81]  R. Elashoff,et al.  Value of the new bone classification system in pediatric renal osteodystrophy. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[82]  A. Anarat,et al.  The Cardiovascular Comorbidity in Children with Chronic Kidney Disease (4C) study: objectives, design, and methodology. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[83]  Y. Frishberg,et al.  A comprehensive study of cardiovascular risk factors, cardiac function and vascular disease in children with chronic renal failure. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[84]  V. Jorgetti,et al.  Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[85]  M. Amling,et al.  Bone mineralization defects and vitamin D deficiency: Histomorphometric analysis of iliac crest bone biopsies and circulating 25‐hydroxyvitamin D in 675 patients , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[86]  I. Salusky,et al.  Sevelamer carbonate increases serum bicarbonate in pediatric dialysis patients , 2010, Pediatric Nephrology.

[87]  J. Adams,et al.  Update in vitamin D. , 2010, The Journal of clinical endocrinology and metabolism.

[88]  M. Saleem,et al.  Middle-term use of Cinacalcet in paediatric dialysis patients , 2010, Pediatric Nephrology.

[89]  M. Kuro-o,et al.  The Klotho gene family as a regulator of endocrine fibroblast growth factors , 2009, Molecular and Cellular Endocrinology.

[90]  R. Kuroki,et al.  Anti‐FGF23 Neutralizing Antibodies Show the Physiological Role and Structural Features of FGF23 , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[91]  M. Wolf,et al.  Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. , 2008, The New England journal of medicine.

[92]  G. Kundt,et al.  Cinacalcet for secondary hyperparathyroidism in children with end-stage renal disease , 2008, Pediatric Nephrology.

[93]  A. Freemont,et al.  Bone histomorphometry in children prior to commencing renal replacement therapy , 2008, Pediatric Nephrology.

[94]  D. Silverstein,et al.  Cinacalcet is efficacious in pediatric dialysis patients , 2008, Pediatric Nephrology.

[95]  M. Roszkowska-Blaim,et al.  Determinants of the intima–media thickness in children and adolescents with chronic kidney disease , 2008, Pediatric Nephrology.

[96]  M. Mohammadi,et al.  The parathyroid is a target organ for FGF23 in rats. , 2007, The Journal of clinical investigation.

[97]  H. Armbrecht,et al.  25-Hydroxyvitamin D(3) suppresses PTH synthesis and secretion by bovine parathyroid cells. , 2006, Kidney international.

[98]  P. Houillier,et al.  Inter-method variability in PTH measurement: implication for the care of CKD patients. , 2006, Kidney international.

[99]  G. Eknoyan,et al.  Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). , 2006, Kidney international.

[100]  A. Edefonti,et al.  Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines , 2005, Pediatric Nephrology.

[101]  Y. Takeuchi,et al.  Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. , 2004, The Journal of clinical investigation.

[102]  F. Dekker,et al.  Severe bone disease and low bone mineral density after juvenile renal failure. , 2003, Kidney international.

[103]  M. Bahner,et al.  Advanced Coronary and Carotid Arteriopathy in Young Adults With Childhood-Onset Chronic Renal Failure , 2002, Circulation.

[104]  Alan D. Martin,et al.  Calcium Accretion in Girls and Boys During Puberty: A Longitudinal Analysis , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[105]  T. Meitinger,et al.  Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23 , 2000, Nature Genetics.

[106]  R. Elashoff,et al.  Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. , 2000, The New England journal of medicine.